| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.
|
JAMA
|
2010
|
4.71
|
|
2
|
Variation of breast cancer risk among BRCA1/2 carriers.
|
JAMA
|
2008
|
3.30
|
|
3
|
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.
|
J Clin Oncol
|
2006
|
3.00
|
|
4
|
Advanced hepatocellular carcinoma: which staging systems best predict prognosis?
|
J Clin Oncol
|
2010
|
2.81
|
|
5
|
Radiation exposure, the ATM Gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study.
|
J Natl Cancer Inst
|
2010
|
1.91
|
|
6
|
Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2.
|
J Clin Oncol
|
2010
|
1.85
|
|
7
|
Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer.
|
J Clin Oncol
|
2010
|
1.80
|
|
8
|
Dose to the contralateral breast from radiotherapy and risk of second primary breast cancer in the WECARE study.
|
Int J Radiat Oncol Biol Phys
|
2008
|
1.58
|
|
9
|
Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.
|
J Clin Oncol
|
2015
|
1.56
|
|
10
|
Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer.
|
Cancer
|
2011
|
1.53
|
|
11
|
Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma.
|
J Clin Oncol
|
2009
|
1.50
|
|
12
|
Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study.
|
Hum Mutat
|
2010
|
1.40
|
|
13
|
Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma.
|
J Clin Oncol
|
2010
|
1.37
|
|
14
|
BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer.
|
Cancer
|
2014
|
1.32
|
|
15
|
Rare germline mutations in PALB2 and breast cancer risk: a population-based study.
|
Hum Mutat
|
2012
|
1.26
|
|
16
|
Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study.
|
J Natl Cancer Inst
|
2007
|
1.18
|
|
17
|
Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study.
|
J Clin Oncol
|
2012
|
1.13
|
|
18
|
A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors.
|
Cancer
|
2012
|
1.13
|
|
19
|
Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium.
|
Gastrointest Cancer Res
|
2013
|
1.13
|
|
20
|
A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus.
|
Cancer
|
2010
|
1.12
|
|
21
|
Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer.
|
Breast Cancer Res Treat
|
2010
|
1.11
|
|
22
|
Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer.
|
Cancer
|
2011
|
1.05
|
|
23
|
Response to neoadjuvant chemotherapy does not predict overall survival for patients with synchronous colorectal hepatic metastases.
|
Ann Surg Oncol
|
2009
|
1.04
|
|
24
|
RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer.
|
Cancer
|
2014
|
1.03
|
|
25
|
KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases.
|
Cancer
|
2014
|
1.02
|
|
26
|
Variants in the ATM gene associated with a reduced risk of contralateral breast cancer.
|
Cancer Res
|
2008
|
1.00
|
|
27
|
Alcohol intake and cigarette smoking and risk of a contralateral breast cancer: The Women's Environmental Cancer and Radiation Epidemiology Study.
|
Am J Epidemiol
|
2009
|
1.00
|
|
28
|
Reproductive history and risk of second primary breast cancer: the WECARE study.
|
Cancer Epidemiol Biomarkers Prev
|
2007
|
0.99
|
|
29
|
Endoscopic ultrasound can improve the selection for laparoscopy in patients with localized gastric cancer.
|
J Am Coll Surg
|
2008
|
0.98
|
|
30
|
Variants in activators and downstream targets of ATM, radiation exposure, and contralateral breast cancer risk in the WECARE study.
|
Hum Mutat
|
2011
|
0.98
|
|
31
|
Pretreatment Neutrophil to Lymphocyte Ratio Independently Predicts Disease-specific Survival in Resectable Gastroesophageal Junction and Gastric Adenocarcinoma.
|
Ann Surg
|
2016
|
0.98
|
|
32
|
A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma.
|
Invest New Drugs
|
2010
|
0.95
|
|
33
|
A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer.
|
Cancer
|
2012
|
0.93
|
|
34
|
A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma.
|
Ann Surg
|
2014
|
0.92
|
|
35
|
Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine.
|
Am J Clin Oncol
|
2011
|
0.92
|
|
36
|
Single nucleotide polymorphisms associated with risk for contralateral breast cancer in the Women's Environment, Cancer, and Radiation Epidemiology (WECARE) Study.
|
Breast Cancer Res
|
2011
|
0.92
|
|
37
|
Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report.
|
Eur J Cancer
|
2013
|
0.90
|
|
38
|
Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer.
|
Cancer Chemother Pharmacol
|
2008
|
0.89
|
|
39
|
Risk of contralateral breast cancer associated with common variants in BRCA1 and BRCA2: potential modifying effect of BRCA1/BRCA2 mutation carrier status.
|
Breast Cancer Res Treat
|
2010
|
0.83
|
|
40
|
Predictive molecular markers for colorectal cancer patients with resected liver metastasis and adjuvant chemotherapy.
|
Gastroenterology
|
2007
|
0.82
|
|
41
|
Reproductive factors and risk of contralateral breast cancer by BRCA1 and BRCA2 mutation status: results from the WECARE study.
|
Cancer Causes Control
|
2010
|
0.82
|
|
42
|
Reproductive status at first diagnosis influences risk of radiation-induced second primary contralateral breast cancer in the WECARE study.
|
Int J Radiat Oncol Biol Phys
|
2012
|
0.81
|
|
43
|
Oral contraceptives, postmenopausal hormones, and risk of asynchronous bilateral breast cancer: the WECARE Study Group.
|
J Clin Oncol
|
2008
|
0.80
|
|
44
|
Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab.
|
Ann Surg Oncol
|
2013
|
0.79
|
|
45
|
Incidence of chemotherapy-induced amenorrhea in premenopausal women treated with adjuvant FOLFOX for colorectal cancer.
|
Clin Colorectal Cancer
|
2013
|
0.78
|
|
46
|
Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study.
|
Breast Cancer Res Treat
|
2009
|
0.77
|
|
47
|
Phase II trial of cetuximab plus cisplatin and irinotecan in patients with cisplatin and irinotecan-refractory metastatic esophagogastric cancer.
|
Am J Clin Oncol
|
2014
|
0.77
|
|
48
|
c-MET and HGF mRNA expression in hepatocellular carcinoma: correlation with clinicopathological features and survival.
|
Anticancer Res
|
2013
|
0.77
|
|
49
|
A Nonrandomized, Phase II Study of Sequential Irinotecan and Flavopiridol in Patients With Advanced Hepatocellular Carcinoma.
|
Gastrointest Cancer Res
|
2012
|
0.77
|
|
50
|
O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors.
|
Pancreas
|
2017
|
0.75
|
|
51
|
Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated.
|
Pancreas
|
2016
|
0.75
|
|
52
|
O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors.
|
Pancreas
|
2017
|
0.75
|
|
53
|
30-day-or-sooner readmissions of gastrointestinal medical oncology patients following cancer center inpatient service discharge: characteristics and preventability.
|
Hosp Pract (1995)
|
2014
|
0.75
|